Document is current

Article History

Received: 3 June 2026

Accepted: 3 July 2026

First Online: 9 September 2026

Declarations

Conflict of interest: E. Halilbasic served as speaker and/or advisory board member for Falk, Ipsen, Gilead, and received travel support from Falk, Ipsen, Gilead. E. Tatscher served as a speaker and/or advisory board member for Gilead, Ipsen, Takeda, and Falk, and received travel support from Ipsen and Gilead. E. Aigner served as speaker and/or advisory board member for Sanofi-Aventis, Gilead, Eli Lilly, Boehringer, Bayer, Falk, Amicus, Takeda, and Roche, and received travel support from Sanofi-Aventis, Gilead, Eli Lilly, Boehringer, Bayer, Falk, Amicus, Takeda, and Roche. L. Burghart received grant support from Gilead, served as a speaker and/or consultant and/or advisory board member for Gilead, Ipsen and AbbVie, and received travel support from Eli Lilly, Gilead and Ipsen. I. Graziadei served as a speaker and/or advisory board member for Gilead, Ipsen, AbbVie, Roche, Alfasigma, Intercept-Advanz; AstraZeneca and Falk, and received travel support from Gilead, Ipsen and Roche. S. Hametner-Schreil served as speaker and/or advisory board member for Falk, Ipsen, Gilead, Abbvie, Roche and received travel support from Roche, Abbvie and Gilead. B.S. Hofer received travel support by Ipsen and Falk, speaking honoraria from Gilead and honoraria for educational materials from Ipsen. H. Hofer served as a speaker and/or advisory board member for Abbvie, Falk, Gilead, Ipsen, Eli-Lilly, Boehringer-Ingelheim, and Madrigal, and received travel support from Abbvie, Falk, Gilead, Ipsen and Eli-Lilly. A. Maieron served as a speaker and/or advisory board member for Gilead, Ipsen, Intercept; Astra Zeneca, Roche and Falk, and received travel support from Ipsen, Gilead and Roche. M. Mandorfer received grant support from Echosens, served as a speaker and/or consultant and/or advisory board member for AstraZeneca, Boehringer Ingelheim, Chiesi, Echosens, Eli Lilly, Ipsen, Madrigal, Takeda, and W. L. Gore & Associates, and received travel support from Ipsen. M. Peck-Radosavljevic served as speaker and/or advisory board member for AstraZeneca, BMS, Boehringer-Ingelheim, Eli Lilly, Eisai, Falk, Gilead, Ipsen, Intercept-Advanz, Merz, MSD, Roche, Sanofi, Shionogi, and Sobi. B. Schaefer received grant support from Astro Pharma and speaker fees from Pharmacosmos, Chiesi and Takeda, as well as travel support from Abbvie. M. Stradner received grant support from Novartis, and Pharming and served as speaker and/or advisory board member for AbbVie, Amgen, Astra Zeneca, BMS, Boehringer Ingelheim, CSL Behring, GSK, Janssen, Eli Lilly, GSK, Janssen, Eli Lilly, MSD, Novartis, Pfizer, Roche, Takeda, and UCB. He. S. Traussnigg served as speaker and/or advisory board member for Sanofi. M. Wagner served as a speaker and/or advisory board member for Astra-Zeneca, Boehringer-Ingelheim, Ipsen, Madrigal, Roche, received grant support from Falk, and travel support from Falk, Gilead, Ipsen, Roche. H. Zoller received grant support from Pharmacosmos, Novo Nordisk, served as speaker for Acino, Pierre Fabre, Falk, Menarini, Kedrion and as consultant for Novo Nordisk, Kedrion, Pharmacosmos, Pierre Fabre, Astra Zeneca, and received travels support from Pharmacosmos and Falk. P. Fickert received grant support from Falk, lntercept, Janssen, Pliant, Gilead, and Ipsen, served as a speaker and/or consultant and/or advisory board member for Sanofi-Aventis, Gilead, Merz, Takeda, Roche, Ipsen, and Falk. He is also co-inventor of patents on the medical use of 24-norursodeoxycholic acid (service inventions as employee) filed by the Medical University of Graz. M. Trauner received grant support from Albireo, Alnylam, Cymabay, Falk, Genentech, Gilead, Intercept, MSD, Takeda and UltraGenyx, served as a speaker and/or consultant and/or advisory board member for AbbVie, Albireo, Agomab, Alfasigma, Boehringer Ingelheim, BiomX, Chemomab, Dexoligo Therapeutics, Falk, Genfit, Gilead, GSK, Hightide, Intercept, Ipsen, Janssen, Madrigal, Mirum, MSD, Novartis, Phenex, Pliant, Rectify, Regulus, ProQR Therapeutics, Siemens and Shire; speaker fees from Albireo, Boehringer Ingelheim, Bristol-Myers Squibb, Falk, Gilead, Ipsen, Intercept, Madrigal, Mirum, and MSD, and received travel support from AbbVie, Falk, Gilead, Jannsen Intercept and Ipsen. He is also co-inventor of patents on the medical use of 24-norursodeoxycholic acid (service inventions as employee) filed by the Medical University of Graz. W. Sieghart declares no competing interests.